Cell and immune therapies have transformed the outcomes of patients with lymphoma, but the majority of patients do not have durable benefit. Here, we provide our perspective on key challenges in personalizing cell and immune therapy approaches for lymphoma through discovery, validation, and clinical deployment of micro...
Xu-Bin Li, Christopher R. Flowers, Michael R. Green· Blood Cancer Discovery· 0 citations
Diffuse large B-cell lymphoma (DLBCL), the most common hematologic cancer in the US, is characterized by marked molecular and clinical heterogeneity. African American (AA) and Hispanic patients experience inferior outcomes due to biologic factors that remain poorly understood, in addition to well-described socioecono...
J. Koff, Jonathon B. Cohen, Lee A. D. Cooper et al.· Cancer Epidemiology, Biomark...· 0 citations
The crystal structures of recurrent hotspot mutations in the CREBBP acetyltransferase are solved and it is shown that the arginine 1446 hotspot has a unique impact on substrate binding and acetyltransferase activity.
Wen-Chao Zhang, Hao-Peng Yang, Ariel E. Mechaly et al.· Proceedings of the National...· 0 citations
The clinical utility and acceptable TAT of a comprehensive WES and RNA-seq assay for LBCL managed in routine clinical practice are demonstrated and support the real-world feasibility of using integrated WES and RNA-seq to define molecular subgroups, guide clinical decision-making at the time of a new line of therapy, a...
Dai Chihara, Kumudha Balakrishnan, G. Masand et al.· Blood Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
